Carbapenems such as meropenem are the cornerstone of therapies for life-threatening bacterial infections. Resistance to carbapenems is considered a critical priority by the World Health Organization (WHO) and Centre for Disease Control and Prevention (CDC) because it is a major cause of treatment failure, increased mortality, and huge economic costs.
Bacteria resistant to carbapenems produce beta-lactamase enzymes that render them ineffective. Antabio has set out to resolve this major healthcare issue via its lead clinical stage program MEM-ANT3310. Its innovative serine-beta-lactamase inhibitor ANT3310 represents a significant breakthrough as it completely inhibits a broad range of beta-lactamases, including the Klebsiella pneumoniae carbapenemases (KPC) and oxacillin-hydrolyzing (OXA) type enzymes found in Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB), and restores meropenem activity against these deadly pathogens. This is critical for the treatment of polymicrobial infections such as those causing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
MEM-ANT3310 received qualified infectious disease product (QIDP) status from the FDA in 2019 for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).